Lumicell

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Lumicell, Health/Medical/ Pharmaceuticals, 307 Waverley Oaks Road, Suite 309, Waltham, MA.

Lumicell is a privately held company focused on innovative fluorescence-guided technologies for cancer surgery with the potential to improve patient outcomes and reduce healthcare costs.

08/31/2026

What happens after the tumor is removed can be just as important as removing the tumor itself.

Even after a successful lumpectomy, residual cancer can remain in the surgical cavity—sometimes leading to additional surgery.

In this conversation, Dr. Barry Rosen explains why fluorescence in the lumpectomy cavity is important and how LumiSystem® provides surgeons with real-time information that wasn't previously available to help lower re-excision rates.

Understanding what's happening in the cavity is changing the conversation around breast-conserving surgery—and helping surgeons make more informed intraoperative decisions.

🎥Watch here

Dr. Rosen was compensated by Lumicell to participate in this interview. Please see Important Safety Information in the video.

08/17/2026

"What we've been missing, which we now have with the LumiSystem, is that we can inject a drug into the patient and that can make their cancers fluoresce."
— Barry Rosen, MD, FACS

For years, breast surgeons have relied on the best available techniques to achieve complete tumor removal during lumpectomy. Today, fluorescence-guided imaging is providing another layer of intraoperative information.

In this clip, explains how LumiSystem® enables surgeons to visualize residual cancer in the lumpectomy cavity during surgery—helping identify cancerous tissue that may otherwise go undetected.

▶️ Watch Dr. Rosen explain why this innovation has the potential to change the future of breast-conserving surgery.

Dr. Rosen was compensated by Lumicell to participate in this interview. Please see Important Safety Information in the video.

08/14/2026

Lumicell is proud to announce that we have been named a finalist for the 2026 Galien Foundation “Best Medical Technology” Award! 🎉

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation that improves the state of human health.

Lumicell is honored to be among 23 finalists selected in the Best Medical Technology category. This recognition reflects the dedication of our team and our commitment to advancing innovation in breast cancer surgery.

Read the press release here: https://www.prnewswire.com/news-releases/the-galien-foundation-announces-2026-prix-galien-usa-nominees-for-best-digital-health-solution-best-medical-technology-incubators-accelerators-and-equity-and-best-startup-302850770.html?tc=eml_cleartime

08/10/2026

Every lumpectomy comes with a critical question: Has all of the cancer been removed? Even with today's standard techniques, cancerous tissue can remain in the lumpectomy cavity, leading some patients to require additional surgery.

In this video, discusses why complete tumor removal remains one of the greatest challenges in breast-conserving surgery—and why having more information in the operating room matters.

That's why Lumicell developed LumiSystem®: the first and only intraoperative solution that enables surgeons to scan inside the breast cavity for residual cancer that may have otherwise been left behind.

▶️Watch Dr. Rosen explain the challenge—and why innovation in intraoperative imaging is changing the conversation.

Dr. Rosen was compensated by Lumicell to participate in this interview. Please see Important Safety Information in the video.

07/29/2026

Breast cancer care is moving toward more personalized, de-escalated treatment. With less adjuvant therapy, a complete resection at the first operation becomes an even more critical part of care — and finding residual cancer intraoperatively directly supports those personalization decisions.

LumiSystem is the first and only solution to look inside the lumpectomy cavity for cancerous tissue that may have otherwise been left behind, so it can be removed in the initial surgery. Learn more at lumisystem.com

Important Safety Information: Serious hypersensitivity reactions, including anaphylaxis, can occur during or following administration of LUMISIGHT (pegulicianine). Anaphylaxis has occurred in 4/726 (0.6%) of patients in clinical studies. LUMISIGHT is contraindicated in patients with a history of hypersensitivity reactions to pegulicianine. Please see the full Prescribing Information, including Boxed Warning, and Instructions for Use at www.LumiSystem.com.

07/20/2026

We are excited to participate in the Ultimate Oncoplastic Breast Course (UOBC), July 31 – August 2 in Atlanta, GA! This immersive, evidence-based program is designed to help surgeons advance their oncoplastic and reconstructive breast surgery practice through hands-on education.

As breast cancer surgery continues to evolve, education and innovation remain essential to elevating patient outcomes. We're honored to support this unique learning experience alongside leading faculty Jean-Claude Schwartz, MD, PhD and Gustavo Zucca, MD, PhD.

If you’re attending, we look forward to connecting with you and discussing how LumiSystem is helping surgeons gain greater confidence in identifying residual cancer in real-time during breast-conserving surgery.

07/09/2026

Wondering what a case day could look like with LumiSystem?

🔹 1. Pharmacy prepares LUMISIGHT® (pegulicianine)
💉 2. Pre-op administers LUMISIGHT (3-minute IV push)
🔹 3. Surgeon performs standard lumpectomy
🔍 4. Surgeon scans the resection cavity with the LumiSystem probe
🎯 5. If red signal is detected, a targeted shave may be taken—then re-scan to confirm removal
⏱️ Imaging adds ~7 minutes to the procedure.

Contact us at [email protected] to learn how LumiSystem can fit into your surgical workflow.

07/03/2026

This Fourth of July, we celebrate the spirit of innovation, resilience, and dedication that drive progress every day.

We're grateful for the surgeons, healthcare teams and patients who inspire our mission to improve the way breast cancer surgery is performed.

Wishing everyone a safe, happy, and healthy Independence Day! ✨ 🎆

06/29/2026

Residual disease can remain beyond the excised specimen – even when margins are negative.

This can be especially challenging in diffuse or non-palpable disease, where what remains may never intersect with the removed tissue.

See how surgeons are gaining real-time actionable insight into the breast cavity during lumpectomy.

Intraoperative imaging can help identify suspected residual disease – in the moment that matters most. Learn more at https://lumisystem.com/

06/16/2026

Despite advances in imaging and pathology, residual disease can still go undetected during lumpectomy.

In diffuse or nonpalpable DCIS, what remains may never be visible with traditional approaches.

What if you could visualize suspected residual disease - in real time?

Learn about the intraoperative technology that helps surgeons identify what may otherwise be left behind in the breast cavity at https://lumisystem.com/

Address

307 Waverley Oaks Road, Suite 309
Waltham, MA
02452

Telephone

+16174041001

Website

http://www.lumicell.com/, https://lumisystem.com/, http://linktr.ee/lumicellsurg

Alerts

Be the first to know and let us send you an email when Lumicell posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your business to be the top-listed Health & Beauty Business in Waltham?